Renal Tubular Acidosis: Types I–IV

Author: Andrew Bland, MD, MBA, MS

Introduction

Renal tubular acidosis (RTA) represents a group of disorders characterized by impaired renal acid excretion or bicarbonate reabsorption, resulting in non-anion gap (hyperchloremic) metabolic acidosis despite a relatively preserved glomerular filtration rate (GFR). This is the critical distinguishing feature: RTA occurs in the setting of normal or near-normal kidney function, whereas chronic kidney disease (CKD) acidosis develops secondary to declining GFR.

RTA results from dysfunction at one of three main sites:

1. Distal nephron H+ secretion (Type 1) — inability to acidify urine
2. Proximal tubule HCO3 reabsorption (Type 2) — bicarbonaturia at physiologic serum levels
3. Aldosterone-responsive collecting duct (Type 4) — impaired K+ and H+ secretion from hyperkalemia

Historically, Type 3 RTA was described as a mixed proximal-distal defect, but this classification is now abandoned except in rare carbonic anhydrase II deficiency.

Overview Comparison Table: RTA Types at a Glance

Type 1: Distal Renal Tubular Acidosis (dRTA)

Pathophysiology

Type 1 RTA results from the failure of the alpha-intercalated (α-intercalated) cells of the collecting duct to secrete hydrogen ions into the tubular lumen, preventing appropriate urine acidification despite systemic acidosis. The collecting duct normally lowers urine pH to as low as 4.5. In dRTA, urine pH remains inappropriately alkaline (> 5.5).

Three distinct pathophysiologic mechanisms:

1. Secretory (H+-ATPase) Defect — The most common mechanism. The H+-ATPase pump in the apical membrane of α-intercalated cells is dysfunctional or downregulated. Genetic mutations (ATP6V1B1, ATP6V0A4) or acquired disease (Sjogren, amphotericin B) damage the pump.
2. Gradient (Back-Leak) Defect — H+ leaks back across an abnormally permeable collecting duct epithelium, negating the pH gradient.
3. Voltage (Lumen-Negative) Defect — H+ secretion depends on a lumen-negative transepithelial voltage. Mutations affecting claudins or SLC4A1 can abolish this voltage gradient.

The low urine citrate occurs because citrate reabsorption is enhanced in acidosis, and citrate is consumed in buffering. This removes a key inhibitor of calcium oxalate crystallization, predisposing to nephrolithiasis and nephrocalcinosis.

Etiologies of Type 1 RTA

Autoimmune Disorders

• Sjogren syndrome (#1 autoimmune cause) — autoantibodies against H+-ATPase subunits and carbonic anhydrase II; dRTA in up to 30% of Sjogren patients
• Systemic lupus erythematosus (SLE)
• Rheumatoid arthritis
• Primary biliary cholangitis (PBC)
• Autoimmune hepatitis
• Graves disease and other thyroiditis

Genetic/Hereditary Forms

• ATP6V1B1 mutations (autosomal recessive) — encodes B1 subunit of H+-ATPase; presents with dRTA + sensorineural hearing loss (deaf-RTA syndrome)
• ATP6V0A4 mutations (autosomal recessive) — encodes a4 subunit
• SLC4A1 mutations (autosomal dominant or recessive) — encodes AE1 (band 3 protein); can present as dominant dRTA or hereditary spherocytosis
• Medullary sponge kidney (MSK) — congenital malformation with tubular dilations

Medications

• Amphotericin B — creates pores in collecting duct epithelium allowing H+ back-leak and K+ wasting; sometimes reversible if caught early
• Lithium (chronic use → collecting duct damage)
• Ifosfamide (cumulative toxicity)
• Toluene ("glue sniffing") — initially presents as high-AG acidosis (hippuric acid), then converts to NAGMA/RTA
• NSAIDs (chronic use)

Nephrocalcinosis Disorders

• Medullary sponge kidney
• Primary hyperparathyroidism
• Vitamin D intoxication

Tubulointerstitial Disease

• Chronic pyelonephritis or reflux nephropathy
• Obstructive uropathy
• Renal allograft rejection
• Sickle cell disease

Clinical Features and Presentation

Hypokalemia — Often prominent (K+ typically 2.5–3.5 mEq/L). The mechanism is counterintuitive: because H+ secretion is blocked, the collecting duct increases K+ secretion via principal cells as an alternative cation to "balance" the lack of H+.

Nephrocalcinosis and Nephrolithiasis — Up to 75% of dRTA patients develop kidney stones (usually calcium phosphate) or medullary nephrocalcinosis. The mechanism involves: (1) high urine pH favoring calcium phosphate precipitation, (2) low urine citrate (loss of stone inhibitor), and (3) high urine calcium from chronic bone buffering.

Growth Retardation in Children — Chronic acidosis impairs linear growth through increased protein catabolism, decreased growth hormone sensitivity, and bone disease from chronic buffering.

Bone Disease — Chronic metabolic acidosis is buffered by bone (osteoclast activation, mineral mobilization), leading to osteomalacia and osteoporosis. Children develop rickets.

Diagnosis of Type 1 RTA

1. Step 1: Establish NAGMA — AG = Na − (Cl + HCO3); normal AG = 8–14 mEq/L
2. Step 2: Confirm Inability to Acidify Urine — Urine pH > 5.5 in the setting of serum pH < 7.35 and HCO3 < 20 is pathognomonic
3. Step 3: Calculate Urine Anion Gap (UAG)
   UAG = (Na + K) − Cl
   In Type 1 RTA: UAG is positive (+5 to +20)
4. Step 4: Check Serum and Urine Electrolytes — Serum K+ < 3.5; serum Cl high relative to HCO3
5. Step 5: Urine-Blood PCO2 Gradient (Modern functional test) — Give oral NaHCO3 for 3 days; gradient < 30 mmHg indicates impaired distal acidification = dRTA. This test has replaced the older NH4Cl loading test.
6. Step 6: Screen for Underlying Etiology — ANA, anti-Ro/La, RF (Sjogren); audiometry; renal imaging; serum calcium, PTH; urine citrate level

Treatment of Type 1 RTA

Goal: Correct acidosis to pH > 7.35 and HCO3 > 20, normalize serum K+, prevent stone formation, and treat underlying etiology.

Alkali Therapy — Cornerstone of Treatment:

• Dose: 1–2 mEq/kg/day (divided into 3–4 doses)
• Much lower dose than Type 2 because there is no bicarbonaturia wasting
• Options:
  • Sodium bicarbonate: 650 mg tablet = 7.7 mEq; take 3× daily (~23 mEq/day)
  • Sodium citrate (Shohl solution)
  • Potassium citrate (preferred): 1080 mg tablet = 10 mEq; addresses acidosis AND K+ depletion AND low urine citrate

Monitoring: Serum electrolytes every 2–4 weeks initially; target K+ 3.5–4.5 and HCO3 > 22; 24-hour urine citrate (target > 200 mg/day); periodic renal imaging.

Type 2: Proximal Renal Tubular Acidosis (pRTA)

Pathophysiology

Type 2 RTA results from reduced bicarbonate reabsorption in the proximal tubule, normally responsible for reclaiming approximately 85% of filtered HCO3. The hallmark pathophysiologic feature is a reduced renal threshold for bicarbonate. In healthy people, the threshold is around 26 mEq/L. In Type 2 RTA, this threshold is lowered to 14–18 mEq/L.

This means:

• As serum HCO3 falls from 26 toward 14 mEq/L, the kidney cannot reabsorb all filtered HCO3, so bicarbonaturia develops
• Bicarbonaturia continues until serum HCO3 falls to the new, lower threshold
• At the new steady state, all filtered HCO3 is reabsorbed and the urine becomes acid (pH < 5.5)

Mechanisms of Reduced HCO3 Reabsorption

1. Carbonic Anhydrase Deficiency — Genetic (CA II/CA IV) or pharmacologic (acetazolamide, topiramate)
2. H+-ATPase Dysfunction — Genetic mutations impairing proximal H+ secretion
3. Impaired Apical Membrane Transport — SLC4A4 mutations (NBCe1) reduce Na-HCO3 cotransporter; results in Type 2 RTA + ocular manifestations
4. Carbonic Anhydrase II Deficiency (Type 3) — Autosomal recessive; features of both Type 2 and Type 1 RTA + osteopetrosis + cerebral calcifications

Etiologies of Type 2 RTA

Isolated Type 2 RTA (Uncommon)

• Genetic: SLC4A4 mutations (with ocular abnormalities), CA II deficiency
• Medications: Acetazolamide, topiramate, dorzolamide

Type 2 RTA as Part of Fanconi Syndrome (More Common)

Fanconi syndrome is generalized proximal tubule dysfunction affecting glucose, amino acids, phosphate, urate, and bicarbonate transport.

1. Multiple myeloma — Light chain deposit disease; most common adult cause of acquired Fanconi + Type 2 RTA
2. Tenofovir (TDF) — Mitochondrial toxin in proximal tubule cells; dose-dependent; usually resolves if discontinued early
3. Ifosfamide — Fanconi syndrome in 20–30% of patients; often irreversible
4. Heavy Metals — Lead, mercury, cadmium
5. Cystinosis — Most common inherited cause in children; lysosomal storage disorder; treatable with cysteamine
6. Lowe syndrome — X-linked OCRL mutations; developmental delay, congenital cataracts, renal disease
7. Wilson disease — Copper overload affecting proximal tubule

Clinical Features of Type 2 RTA

Hypokalemia — Impaired proximal Na reabsorption delivers more Na to the distal nephron; the collecting duct takes up Na via ENaC, and K+ is secreted in exchange.

Osteomalacia and Rickets — Prominent feature, especially with Fanconi syndrome. Hyperphosphaturia (FEHPO4 > 20%) leads to phosphate depletion and severe bone disease.

Diagnosis of Type 2 RTA

1. Establish NAGMA — HCO3 typically 14–18 (nadir)
2. Assess for Fanconi Syndrome — Glucosuria (normal serum glucose), aminoaciduria, uricosuria (FE urate > 10%), phosphaturia (FEHPO4 > 20%)
3. Calculate UAG — Typically positive
4. Fractional Excretion of HCO3 (FEHCO3) — The Definitive Test
   FEHCO3 = (Urine HCO3 × Serum Cr) / (Serum HCO3 × Urine Cr) × 100%
   
   Normal: < 5% | Type 2 RTA: > 15% (after HCO3 loading)
5. Screen for Etiology — Medications review; myeloma screening (SPEP, FLC); heavy metals; genetic causes (cystinosis, Wilson)

Treatment of Type 2 RTA

Alkali Therapy — High-Dose Requirement:

• Dose: 10–15 mEq/kg/day (much higher than Type 1)
• Reason: significant bicarbonaturia continues while serum HCO3 is being raised
• Example: 60 kg patient may need 600–900 mEq/day divided throughout the day
• Preferred agents: Potassium citrate (if hypokalemia present), sodium citrate

Thiazide Diuretics — Adjunctive Therapy:

• Thiazides cause mild volume depletion, which reflexively increases proximal tubule Na (and coupled HCO3) reabsorption
• Hydrochlorothiazide 25 mg daily
• Reduces alkali dose needed
• Caution: thiazides cause hypokalemia — adjust K+ supplementation

If Fanconi: Phosphate supplementation (1–3 grams daily) + Vitamin D (cholecalciferol 2,000–4,000 IU daily or calcitriol 0.5–1 mcg BID if severe hypophosphatemia).

Type 3: Mixed RTA (Historical — Carbonic Anhydrase II Deficiency)

Type 3 RTA is a rare genetic condition caused by mutations in the CA2 gene. Because CA II is essential for both proximal HCO3 reabsorption (Type 2 mechanism) and distal H+ secretion (Type 1 mechanism), patients have features of both types simultaneously.

Clinical Features

• Osteopetrosis (marble bone disease) — paradoxically dense but weak bones; osteoclasts cannot resorb bone without CA II; increased fracture risk despite dense appearance
• Cerebral calcifications — subcortical white matter and basal ganglia calcifications; variable neurologic manifestations
• RTA features — both distal (inability to acidify, hypokalemia) and proximal (bicarbonaturia, some Fanconi features)

Inheritance and Epidemiology

Autosomal recessive. Extremely rare; mostly in consanguineous families from the Middle East and North Africa. No cases routinely seen in Western practice.

Management

Lifelong alkali therapy (similar to Type 1 but may need higher doses due to proximal component). Supportive care for bone disease. No specific cure.

Type 4: Hyperkalemic Renal Tubular Acidosis

Type 4 RTA is the most common form of RTA in clinical practice (60% of RTA cases), particularly in adults. It is characterized by hyperkalemia rather than hypokalemia, and mild acidosis rather than severe.

Pathophysiology

Type 4 results from dysfunction in the renin-angiotensin-aldosterone system (RAAS) or in the principal cells of the collecting duct.

1. Aldosterone Deficiency (Hyporeninemic Hypoaldosteronism)

Renin production is suppressed (usually from tubulointerstitial disease), leading to low aldosterone. Without aldosterone, principal cells cannot activate ENaC to reabsorb Na and secrete K+.

2. Aldosterone Resistance (Renal Insensitivity)

Aldosterone levels are normal or elevated, but the kidney cannot respond. Either from receptor mutations, medications blocking ENaC/aldosterone receptor, or tubulointerstitial disease.

3. The Hyperkalemia Perpetuates Acidosis

Etiologies of Type 4 RTA

Category A: Aldosterone Deficiency

1. Diabetic Nephropathy (#1 cause) — tubulointerstitial fibrosis suppresses renin; GFR 30–60; prevalence 5–10% of diabetic CKD patients
2. NSAIDs — suppress renin release via prostaglandin inhibition
3. Calcineurin Inhibitors (cyclosporine, tacrolimus) — tubulointerstitial toxicity + renal vasoconstriction; very common post-transplant
4. Heparin (unfractionated and LMWH) — directly suppresses aldosterone synthesis at adrenal cortex
5. Primary Adrenal Insufficiency (Addison Disease) — combined cortisol AND aldosterone deficiency
6. Congenital Adrenal Hyperplasia — 21-hydroxylase deficiency impairs cortisol and aldosterone synthesis
7. ACE Inhibitors / ARBs — suppress aldosterone synthesis; risk factors: diabetics, CKD, combination therapy
8. HIV-Associated Adrenalitis — HIV and opportunistic infections damage adrenal glands

Category B: Aldosterone Resistance

1. MR Antagonists — Spironolactone, eplerenone; hyperkalemia in 10–15% of patients on spironolactone
2. ENaC Blockers:
   • Trimethoprim — blocks ENaC acutely; hyperkalemia within days; very commonly missed
   • Pentamidine — similar mechanism
   • Amiloride, triamterene — intentional K+-sparing diuretics
3. Pseudohypoaldosteronism Type 1 (PHA1) — genetic; autosomal recessive (SCNN1B/G) or dominant (MR gene); high aldosterone but ineffective
4. Pseudohypoaldosteronism Type 2 (PHA2) — WNK1/WNK4 mutations; hyperkalemia + HTN (distinguishing feature)
5. Obstructive uropathy, sickle cell disease, SLE tubulointerstitial nephritis, amyloidosis

Clinical Features

Hyperkalemia (K+ typically 5.5–7 mEq/L) — The most important distinguishing feature. Often asymptomatic at mild levels; can cause sudden cardiac dysrhythmias if severe (> 7).

Mild Metabolic Acidosis — HCO3 typically 15–20 mEq/L (compared to 10–14 in Type 1).

Urine pH Usually < 5.5 — The collecting duct is intact and capable of acidification; the problem is the voltage gradient driving it is reduced.

Diagnosis of Type 4 RTA

1. Recognize the Triad: NAGMA + Hyperkalemia (K+ > 5.5) + Mild acidosis (HCO3 15–20)
2. Calculate UAG: May be positive or negative (less reliably positive than Types 1/2)
3. TTKG (Transtubular Potassium Gradient):
   TTKG = (Urine K × Serum Cr) / (Serum K × Urine Cr)
   Normal at high serum K+: > 8–10
   In Type 4 RTA: < 6–8 despite high serum K+
4. Differentiate Aldosterone Deficiency from Resistance:

Treatment of Type 4 RTA

A. If Aldosterone Deficiency (Low Renin, Low Aldosterone)

Fludrocortisone (synthetic mineralocorticoid):

• Dose: 0.1–0.2 mg daily
• Mechanism: activates MR → opens ENaC → Na reabsorption → K+ secretion
• Target K+ 4–5 mEq/L
• Side effects: hypertension, edema, hypokalemia if overdosed
• Caution: avoid in HF, ascites, existing HTN
• May combine with loop diuretic (furosemide 40–80 mg daily)

B. If Aldosterone Resistance

Fludrocortisone will NOT work. Instead:

• Loop diuretics (furosemide 40–160 mg daily) — increase distal Na delivery and K+ secretion
• Dietary K+ restriction (< 2 grams/50 mEq daily) — avoid bananas, oranges, tomatoes, potatoes, nuts, salt substitutes
• Sodium bicarbonate (1–2 mEq/kg/day) for acidosis component
• Stop offending medications when possible

Potassium Binders (Newer Agents)

Diagnostic Algorithm for RTA

RTA in Special Populations

RTA in Pregnancy

• Pregnancy induces mild respiratory alkalosis (PCO2 28–32 mmHg); normal serum HCO3 is 18–21
• Type 1 RTA may worsen; requires increased alkali therapy
• Type 4 RTA: avoid ACEi/ARB, NSAIDs, spironolactone during pregnancy
• More frequent K+ monitoring in Type 4

RTA in Pediatric Patients

• Cystinosis — most common cause of Type 2 RTA with Fanconi in children; without treatment, ESRD by age 10; with cysteamine therapy, progression delayed
• Genetic Type 1 RTA with Deafness (ATP6V1B1) — usually detected by newborn hearing screening
• Chronic RTA impairs linear growth; alkali therapy improves growth velocity

RTA vs CKD Metabolic Acidosis

Clinical Pearls and Teaching Points

Summary Table: RTA Types — Quick Reference

References

1. Karet FE. Mechanisms in hyperkalemic renal tubular acidosis. J Am Soc Nephrol. 2009;20(2):251–257. PubMed
2. Batlle DC, Hizon M, Cohen E, Gutterman C, Gupta R. The use of the urine anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med. 1988;318(10):594–599. PubMed
3. Palmer BF, Clegg DJ. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. Am J Med. 2004;116(1):15–21. PubMed
4. Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010;6(5):274–285. PubMed
5. Batlle D, Haque SK. Urine anion gap in the evaluation of hyperchloremic metabolic acidosis. Clin J Am Soc Nephrol. 2018;13(5):773–781. PubMed
6. Rodriguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002;13(8):2160–2170. PubMed
7. Adrogue HJ, Madias NE. Management of life-threatening acid-base disorders. N Engl J Med. 1998;338(1):26–34. PubMed
8. Eiam-Ong S, Spasovski G, Gansevoort RT. Renal tubular acidosis. Kidney Int. 2019;96(2):327–341. PubMed
9. Fives CC, Sokolove PE, Hernandez JJ. Amphotericin B-induced renal tubular acidosis and hypokalemia. West J Med. 1999;170(3):159–161. PubMed
10. Kamel KS, Ethier JH, Richardson RM, Bear RA, Halperin ML. Urine electrolytes and osmolality: when and how to use them. Am J Nephrol. 1990;10(2):89–102. PubMed

© 2025 Andrew Bland, MD, MBA, MS — Urine Nephrology Now